<unk> (Gocovri) is a weak uncompetitive antagonist of the NMDA receptor that is FDA approved for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.   Common adverse reactions include hallucination, dizziness, dry mouth, peripheral edema, constipation, fall, and orthostatic hypotension.
Amantadine 
Rimantadine
Tromantadine
Visnadine
Azatadine
Alcaftadine
Tecovirimat
Rupatadine